• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 202
  • 188
  • 21
  • 21
  • 11
  • 10
  • 9
  • 7
  • 7
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • Tagged with
  • 546
  • 170
  • 131
  • 110
  • 86
  • 71
  • 51
  • 49
  • 48
  • 44
  • 41
  • 39
  • 39
  • 35
  • 34
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
531

Impacto da imunização materna com Bordetella pertussis na resposta celular e nos níveis de anticorpos IgG séricos e IgA secretores adquiridos passivamente pelo recém-nascido / Impact of maternal immunization with Bordetella pertussis in cellular response and in serum IgG and secretory IgA antibody levels acquired passively by the newborn

Laila Lima 08 August 2018 (has links)
A imunização materna com a vacina acelular para pertussis (dTpa) é uma intervenção adicional que visa fornecer proteção aos recém-nascidos (RN). No entanto, tem sido relatado que altos níveis de anticorpos adquiridos por transferência placentária podem afetar adversamente a resposta imune desses RN após a imunização ativa, devido ao mascaramento antigênico. Neste estudo, avaliamos a aquisição passiva neonatal de anticorpos específicos para pertussis e sua influência na resposta imune celular dos neonatos. A casuística foi composta por gestantes vacinadas com a vacina dTpa (grupo caso, n=66) ou por gestantes que não receberam a vacina (grupo controle, n=101). As concentrações de anticorpos IgG séricos específicos para Bordetella pertussis total (Bp), toxina pertussis (PT), hemaglutinina filamentosa (FHA) e pertactina (PRN) foram quantificadas em soro materno e de cordão umbilical de seu respectivo RN, e as concentrações de anticorpos IgA específicos para Bp e PT foram dosadas nas amostras de colostro por meio de ensaio imunoenzimático. A responsividade dos linfócitos do sangue neonatal foi avaliada após estimulação ex vivo com Bp inativada por citometria de fluxo com o intuito de detectar a proliferação, produção de citocinas e fenótipo de ativação dos linfócitos T em um contexto de altas concentrações de IgG específicas adquiridas após a vacinação materna. As concentrações de anticorpos IgG anti-Bp, PT, FHA e PRN foram maiores nas amostras de soro materno e de cordão umbilical do grupo caso quando comparadas ao grupo controle (p < 0,0001), com índices de correlação positivos em ambos os grupos para todos os antígenos estudados (p < 0,0001). As vacinações realizadas entre 26 e 31 semanas de gestação foram associadas com as melhores taxas de transferência placentária, embora índices significativamente menores foram detectados no grupo caso (p < 0,01). As concentrações de anticorpos IgA anti-Bp e anti-PT no colostro não foram afetadas pelo estado vacinal da parturiente. Os ensaios de cultura celular revelaram que os RN responderam ao estímulo com Bp, com maior expressão de CD40L, CD69 e proliferação de células T CD4, em comparação com células não estimuladas. Também foi observada uma menor resposta Th1, enquanto a resposta Th2 foi preservada, em comparação com os adultos, mas sem diferenças entre os grupos de neonatos em nenhum dos parâmetros estudados. Nossos resultados indicam que níveis mais altos de anticorpos IgG específicos para B. pertussis no soro dos RN após a vacinação materna não afetam a resposta imune neonatal mediada por células / Maternal immunization with pertussis acellular vaccine (Tdap) is an additional intervention that provides protection to newborns. However, it has been reported that high antibody levels acquired via placental transfer may adversely affect the immune response of newborns after active immunization due to epitope masking. In this study, we evaluated neonatal passive acquisition of pertussis-specific antibodies and their influence on the neonatal cell-mediated immune response. The sample consisted of pregnant women vaccinated with the Tdap vaccine (case group, n=66) or pregnant women who received no vaccine (control group n=101). Whole-cell Bordetella pertussis (Bp), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)-specific serum IgG concentrations were quantified in paired maternal-cord sera, and Bp- and PT-specific IgA concentrations were evaluated in colostrum samples by immunoenzymatic assay. Ex vivo neonatal blood lymphocyte responsiveness after inactivated Bp stimulation was assessed using flow cytometry to detect the proliferation, cytokine production and activation phenotype of T lymphocytes in the context of high specific IgG concentrations acquired after maternal vaccination. Anti-Bp, PT, FHA and PRN IgG antibody concentrations in maternal and cord serum samples from case group were higher than those in control group (p < 0.0001), with positive correlation indexes in both groups for all pertussis antigens (p < 0.0001). Vaccinations performed between 26 and 31 gestation weeks were associated with the best placental transfer ratios, although significantly lower ratios were detected in case group (p < 0.01). Anti-Bp and anti-PT IgA concentrations in colostrum were not affected by vaccine status. Cell culture assays revealed that newborns responded to Bp stimulation with higher expression of CD40L CD69 and CD4+ T cell proliferation compared to unstimulated cells. It was also observed a lower Th1 response, while a preserved Th2 response compared to adults, but there were no differences between neonatal groups for any of the studied parameters. Our results indicate that higher pertussis-specific IgG levels in newborn sera after maternal vaccination do not affect the neonatal cell-mediated immune response
532

Imunogenicidade da vacina meningocócica conjugada do grupo C em adolescentes e adultos jovens com aids / Immunogenicity of a meningococcal serogroup C conjugate vaccine in AIDS adolescents and young adults

Daniela Vinhas Bertolini 27 March 2014 (has links)
Pacientes infectados pelo HIV apresentam resposta de imunogenicidade menor àquela obtida pela população geral com a imunização de rotina. A vacina meningocócica C conjugada é indicada para essa população, não existindo pesquisas prévias que avaliassem a imunogenicidade desta, para esse grupo específico. O estudo realizou essa avaliação comparando a resposta vacinal entre os pacientes infectados e não infectados pelo HIV, as relações dessa resposta com parâmetros clínicos e laboratoriais da infecção pelo vírus e os eventos adversos à vacinação. Utilizou-se as técnicas ensaios de anticorpos bactericidas séricos ou ação bactericida no soro (SBA) e o enzyme-linked immunosorbent assay (ELISA). Tratou-se de um ensaio clínico, envolvendo 92 pacientes, com idades entre 10-20 anos, sendo 43 infectados e 49 não infectados pelo HIV. Após a vacinação, 72,1% do grupo HIV+ e 100% do grupo HIV- foram considerados protegidos. Os pacientes do grupo HIV+ não respondedores à vacinação foram revacinados, tendo sido respondedores a essa nova dose 40% destes. Portanto, 81,4% dos pacientes infectados pelo HIV adquiriram proteção com a vacina (após uma ou duas doses). Foi encontrada correlação da resposta vacinal com o número de esquemas antirretrovirais previamente utilizados e carga viral pré-vacinação, não havendo outras associações com os demais parâmetros clínicos e laboratoriais da infecção pelo HIV. Pacientes com adequada resposta vacinal tenderam a ser os de menor idade. Efeitos colaterais ocorreram em 16,3% no grupo HIV+ e em 44% no HIV-. Conclui-se que a vacina meningocócica C conjugada é segura e efetiva para uso em adolescentes e adultos jovens com aids, embora a resposta de anticorpos seja menor do que a observada em indivíduos saudáveis. Isso indica a necessidade de discussão de novos esquemas de imunização em infectados pelo HIV, objetivando uma proteção mais efetiva contra doença meningocócica / Children and adolescents infected with HIV typically have a weaker response to immunization in comparison with the healthy population. The meningococcal C conjugate vaccine is routinely recommended for those individuals. No studies, however, have evaluated the antibody response to this vaccine in HIV-infected patients yet. In this study, we compared the antibody response to the meningococcal C conjugate vaccine between HIV-infected and HIV-uninfected patients using the serum bactericidal antibody assay (SBA) and the enzyme-linked immunoabsorbent assay (ELISA). Additional objectives were to determine whether the acquired immunity correlated with clinical and laboratory features of HIV infection, and to evaluate the vaccine side effects in this population. This clinical trial included 92 patients aged 10 to 20 years old: 43 HIV-infected and 49 HIV-uninfected patients. After one single dose of the vaccine, 72.1% of the HIV-infected and 100% of the HIV-uninfected patients were considered protected. Of the HIV-infected patients (non-responders in first dose) who received a second dose of the vaccine, only 40% reached protective antibody levels. Overall, 81.4% of the HIV-infected patients reached protective antibody titres (after one or two doses of the vaccine). The antibody response in HIV-infected patients correlated with the number of prior antiretroviral therapy schedules and with the pre-vaccination viral load, but with no other clinical features or laboratory tests. Patients with adequate vaccinal response tended to be younger. Side effects occurred in 16.3% and 44% of the HIV-infected and HIV-uninfected groups, respectively. In conclusion, the meningococcal serogroup C conjugate vaccine proved to be safe and effective in HIV-infected adolescents and young adults, although their antibody response was weaker than that of HIV-uninfected patients. These results suggest that the immunization schedule for HIV-infected patients should be re-evaluated, in order to assure more effective protection against the meningococcal disease in this population
533

Évaluation du processus : analyse de l’évaluabilité et de la mise en œuvre d’une stratégie d’amélioration de la couverture vaccinale au Burkina Faso.

Sanou, Aboubakary 08 1900 (has links)
La vaccination qui est le sujet sur lequel porte cette recherche est une des questions de santé publique les plus importantes; elle fait néanmoins l’objet de nombreuses controverses. Dans le contexte de cette thèse, c’est plutôt l’accès à la vaccination qui est mis en question. La présente recherche vise à analyser une stratégie d’amélioration de la couverture vaccinale à l’aide d’une évaluation de processus extensive en trois étapes faisant suite à une documentation approfondie du contexte. En effet, la recherche analyse les perceptions et les facteurs d’influence de la couverture vaccinale avant l’intervention, les assises conceptuelles et théoriques de cette intervention, l’implantation et la réception de l’intervention et enfin les résultats et les mécanismes mis en œuvre pour les atteindre. Les résultats indiquent que la vaccination s’insère dans l’ensemble des stratégies locales de protection fondées sur des notions endogènes du risque. Ces éléments culturels associés à des facteurs socioéconomiques et aux rapports entre parents et services de santé concourent à expliquer un niveau relativement bas de couverture vaccinale complète de 50% avant l’intervention. L’analyse exploratoire de l’intervention indique que celle-ci intègre une théorie initiale implicite et une philosophie. L’intervention finale était évaluable; cependant, la validation de sa théorie a été compromise par des écarts dans l’implantation. L’approche descriptive montre des taux de réalisation d’activités assez élevés, une atteinte de plus de 95% des cibles et un niveau de réception acceptable, ce qui indique que l’intervention est une stratégie réalisable mais à améliorer. La couverture vaccinale après l’intervention est de 87%; elle est influencée positivement par les niveaux de connaissance élevés des parents et le fait pour les enfants d’être nés dans un centre de santé, et négativement par l’éloignement par rapport au site de vaccination. L’atteinte des résultats suit la procédure principale d’amélioration du niveau de connaissance des parents. Celle-ci est basée sur un mécanisme latent qui est la perception des « opportunités » que fournit la vaccination pour prévenir divers risques sanitaires, sociaux et économiques. Cependant, des approches complémentaires tentent de maximiser les effets de l’intervention en utilisant les pouvoirs conférés aux relais communautaires féminins et la coercition sociale. Cette recherche contribue à éclairer la relation entre l’évaluation du processus et l’analyse de l’évaluabilité, à conceptualiser et opérationnaliser autrement les notions de doses d’intervention administrées et de doses reçues. Sur le plan de la pratique, la recherche contribue à proposer l’amélioration des profils de personnel pour les activités de vaccination et la vulgarisation de la stratégie. Des propositions sont faites pour l’amélioration de l’intervention et l’information des institutions de financement des interventions. / Immunization is one of the most important subjects in public health despite constant on-going controversies. In the context of this research it is more its accessibility that is at issue. This particular research is situated in the perspective of the comprehensive approaches to evaluation and analyses an immunization improvement strategy using a three steps process evaluation after documenting its context. The perceptions and factors influencing immunization coverage before the intervention are assessed, as well as the conceptual and theoretical foundations of the intervention, the implementation and reception of the intervention and mechanisms used to attain the results. The results indicate that immunization is integrated into the local strategies used for protection and grounded in the local concept of risk. Results show also that the context associated with socioeconomic factors and the relations between parents and health services contribute to explain the relatively low complete immunization coverage rate (50.3%) before the intervention. The exploratory analysis indicates that the intervention had an implicit theory and a philosophy. Although the intervention was adequate for an evaluation, discrepancies in the implantation compromised the possibilities of validating its initial theory and philosophy. The descriptive analysis showed that more than 95% of the recipients were reached by the intervention and the received dose of intervention was acceptable indicating that the intervention is a workable strategy that needs to be improved. The complete immunization coverage after the intervention was 87.3%; it was influenced positively by factors including parents’ level of knowledge and the fact that the child was born in a health center, and negatively by the long distances from household to immunization place. The strategies involved in the attainment of the results used parents’ knowledge improvement as a principal procedure. This contains an underlying mechanism mainly related to the perception of the opportunities that immunization permits for preventing various health, social and economic risks. However, complementary approaches tend to maximize intervention outcome by using the power given to female community immunization facilitators and social coercion. The research contributes to highlight the relationship between evaluability assessment and process evaluation, to propose a new conceptual and operational understanding of dose of intervention administered and dose of intervention received. On practical grounds, this research recommended the improvement of the immunization activities staff profile and the widespread adoption of the strategy after it improvement. Indications are provided to improve the intervention and to inform founding agencies.
534

Peut-on donner d’une clause et reprendre de l’autre? Essai sur la cause comme instrument de contrôle de la cohérence matérielle du contrat

Berthold, Gabriel-Arnaud 03 1900 (has links)
No description available.
535

Évaluation du processus : analyse de l’évaluabilité et de la mise en œuvre d’une stratégie d’amélioration de la couverture vaccinale au Burkina Faso

Sanou, Aboubakary 08 1900 (has links)
No description available.
536

Primary health care challenges in Ekurhuleni Metropolitan Municipality

Ndhambi, Mshoni Angeline 01 February 2013 (has links)
OBJECTIVE/ METHOD The study examined implementation challenges faced by primary health care workers within the Ekurhuleni Metropolitan Municipality in Gauteng South Africa. Data collection was based on semi-structured interviews carried out on a purposive sample (n=19) of frontline clinicians working within the district as primary health care practitioners. RESULTS Participants confirmed that work within the primary health care service disproportionately focussed on curative and rehabilitative functions of their roles with little prioritisation of preventive and promotive interventions. Primary identified reasons included, institutional culture that prioritised short-term curative approaches. Clinicians also cited a range of other organisational barriers, such as – poor strategic planning, and a lack of understanding of health promotion and illness prevention. CONCLUSIONS Although the challenges that exist in implementing primary health care are clearly understood, clinicians perceive the solutions for these as being within the control of policy makers and those with power within the organisation. / Health Studies / M.A. (Public Health)
537

Caregivers' perceptions with regard to vaccine preventable diseases / Caregivers' perceptions with regard to vaccine preventable diseases in the City of Tshwane

Maseti, Elizabeth 06 1900 (has links)
This study investigated caregivers' perceptions with regard to vaccine-preventable diseases in terms of six constructs of the Health Belief Model. A qualitative research design that is explorative, descriptive and contextual in nature was employed in order to understand and describe the perceptions influencing access and utilisation of services that lead to missed immunisation opportunities and consequently outbreaks of vaccine-preventable diseases. The data-collection techniques were individual unstructured in-depth interviews, field notes and clinical records. The sample consisted of twenty two (N=22) caregivers who volunteered to be interviewed. The study has highlighted that caregivers' perceptions or cognitive factors play an important role for having children in completing immunisation schedule to protect the public from vaccine-preventable diseases. It is recommended that mass media programmes are needed to address the role of vaccines in reducing high morbidity and mortality rates caused by vaccine preventable diseases and improvement in access to immunisation services. / Health Studies / MPH (Health Studies)
538

Efeito da imunização com enzimas recombinantes do metabolismo de nucleotídeos de Schistosoma mansoni sobre o desenvolvimento da esquistossomose mansônica experimental

Neris, Débora Meira 29 August 2012 (has links)
Made available in DSpace on 2016-08-17T18:39:46Z (GMT). No. of bitstreams: 1 5245.pdf: 1568165 bytes, checksum: 9fc25ff9dc83339e50628c08854efd2c (MD5) Previous issue date: 2012-08-29 / Universidade Federal de Sao Carlos / Schistosimiasis mansoni is a neglected chronic parasitic disease that affects thousands of people worldwide, caused by the trematode Schistosoma mansoni. In the infected host the disease is characterized by the presence of granuloma, imunnopathological response of the cellular infiltration against egg antigens. Thus, the host-parasite relation favors hepatosplenomegaly, acite and hepatic fibrosis. Current chemotherapy is based on the use of Praziquantel (PZQ), used against all species of Schistosoma spp for over 30 years. The main issue is that the PZQ is practically inactive against immature schistosomula and favors the resistance growth of the existent lineages, which makes the study for new drugs and vaccines that can contribute to the control of this disease even more urgent. One of the paths on the search for new therapeutic targets is the study of essential enzymes to the S. mansoni. In particular, it is known that the enzymes Adenylate Kinase 1 and 2 (ADK), Uridine cytidine Kinase 1 and 2 (UCK), Hypoxanthine guanine phosphoribosyltransferase (HGPRT) e Purine nucleoside phosphorilase 1 (PNP) are found on the metabolic pathways of the parasite s nucleotide, participating in the metabolism of purines and pyrimidines. Our goals in this study were to assess the immunization with these enzymes, using the S. mansoni cercariae infected murine model, and subsequently analyze the acting in oviposition and growth of adult worms. Our results showed that the immunization in Balb/c mice with the UCK enzyme was capable of inducing a specific immune response, which favored a significant reduction of the parasitic load (adult worms). However, it was not possible to observe significant reduction in the number of eliminated eggs. Regarding the immunization with PNP and HGPRT enzymes, the mice had a reduction in the number of eggs per gram of feces. The data obtained are considered interesting and can be new targets for immunotherapy against schistosomiasis mansoni. Thereby, new assays must be made with different dosages of the enzymes for a better assessment on how these enzymes modulate the parasitic load through the eggs reduction, reduction in the adult worms retrieving, as well as the antibody levels during the murine infection by the S.mansoni. / A esquistossomose mansônica é uma doença parasitária, crônica e negligenciada que afeta milhares de pessoas ao redor do mundo, causada pelo trematódeo Schistosoma mansoni. No hospedeiro infectado a doença é caracterizada pela presença do granuloma, resultado imunopatológico do infiltrado celular contra antígenos dos ovos A quimioterapia atual é baseada no uso do Praziquantel (PZQ), usado contra todas as espécies de Schistosoma spp há mais de 30 anos. O principal problema é que o PZQ é praticamente inativo contra esquistossomulos imaturos e favorece o desenvolvimento de resistência das linhagens existentes. Um dos caminhos na busca por novos alvos terapêuticos é o estudo de enzimas que são essenciais para o S. mansoni. Em especial, sabe-se que as enzimas Adenilato Quinase 1 e 2 (ADK), Uridina Citidina Quinase 1 e 2 (UCK), Hipoxantina-guanina fosforibosiltransferase (HGPRT) e Purina Nucleosídeo Fosforilase 1 (PNP) são encontradas nas vias metabólicas de nucleotídeos do parasito, participando do metabolismo de purinas e pirimidinas. A estratégia de utilizar enzimas do parasito na esquistossomose mansônica murina foi de avaliar uma resposta induzida por estas enzimas quando aplicadas em camundongos BALB/c e desafiados com cercarias de S. mansoni. Desta forma, avaliamos a fase crônica de camundongos imunizados e infectados com S. mansoni, onde foram analisadas amostras parasitológicas, hematológicas, sorológicas e fluidos da cavidade peritoneal. Nosso objetivo neste estudo foi avaliar a imunização com essas enzimas, usando o modelo murino infectado com cercarias de S. mansoni e posteriormente avaliar a ação na oviposição e desenvolvimento de vermes adultos. Nossos resultados demonstraram que a imunização em camundongos Balb&#8725;c com a enzima UCK foi capaz de induzir uma resposta imune específica, a qual favoreceu a diminuição significativa da carga parasitária (vermes adultos). No entanto, não foi possível observar redução significativa no número de ovos eliminados. Em relação à imunização com as enzimas PNP e HGPRT os camundongos que receberam as imunizações com PNP e HGPRT tiveram redução no número de ovos por grama de fezes. Os dados obtidos são considerados interessantes e podem ser considerados novos alvos para a imunoterapia contra a esquistosomose mansônica. Dessa forma, novos ensaios deverão ser realizados com diferentes doses das enzimas para melhor avaliar como essas enzimas modulam a carga parasitária através da redução de ovos, diminuição na recuperação de vermes adultos, assim como os níveis de anticorpos durante a infecção murina pelo S. mansoni.
539

Análise da imunogenicidade de uma vacina de DNA codificando epitopos CD4 promíscuos e conservados do HIV-1 em camundongos BALB/c e transgênicos para moléculas de HLA classe II / Immunogenicity analysis of a DNA vaccine encoding promiscuous and conserved HIV-1 CD4 epitopes in BALB/c and HLA class II transgenic mice

Susan Pereira Ribeiro 26 August 2010 (has links)
Abordagens atuais no desenho de vacinas contra o HIV-1 estão focadas em imunógenos que codificam proteínas inteiras do HIV-1 e visam induzir respostas citotóxicas específicas. É concebível que vacinas bem-sucedidas devem induzir respostas contra múltiplos epitopos do HIV-1, coincidindo com seqüências das cepas circulantes do vírus, conhecido por sua grande variabilidade genética. Sabe-se que células T CD4+ são necessárias para indução de respostas efetivas de linfócitos T CD8+ citotóxicos. Neste trabalho, nós avaliamos a imunogenicidade de uma vacina de DNA codificando 18 epitopos para linfócitos T CD4+, conservados e ligadores de múltiplas moléculas HLA-DR em camundongos BALB/c e em quatro linhagens de camundongos transgênicos para moléculas de HLA classe II. Os camundongos imunizados apresentaram respostas de amplitude e magnitude significativas com proliferação e secreção de citocinas por linfócitos T CD4+ e T CD8+. Onze dos 18 epitopos para linfócitos T CD4+ presentes na vacina foram reconhecidos pelas linhagens de camundongos transgênicos para moléculas de HLA classe II. Em suma, 17 dos 18 epitopos codificados pela vacina foram reconhecidos. As células induzidas pela vacina apresentaram um perfil polifuncional com tipo 1 de citocinas, incluindo produção de IFN- , TNF- e IL-2. A vacina também induziu células T CD4+ de memória central de longa duração, capazes de fornecer auxílio contínuo para células T CD8 +. Pela capacidade da vacina HIVBr18 de induzir respostas contra múltiplos epitopos de linfócitos T CD4+ conservados que podem ser reconhecidos no contexto de múltiplas moléculas de HLA classe II, esse conceito vacinal pode solucionar o problema da variabilidade genética viral assim como aumentar a cobertura populacional. Portanto, essa vacina, pode ser útil se utilizada isoladamente ou como fonte de auxílio cognato para células T CD8+ HIV-específicas induzidas por outros imunógenos gerando resposta em uma grande proporção dos vacinados / Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that elicit cytotoxic CD8+ responses. It is conceivable that successful vaccines have to elicit responses to multiple epitopes, to match circulating strains of HIV, a virus known for its high genetic variability. It is known that CD4+ T cell responses are necessary for effective CD8+ antiviral responses. Here we assessed the immunogenicity of a DNA vaccine encoding 18 conserved, multiple HLA-DR-binding HIV CD4 epitopes in BALB/c and four strains of HLA class II-transgenic mice. Immunized mice displayed CD4+ and CD8+ proliferative and cytokine T cell responses of significant breadth and magnitude. Eleven out of the 18 encoded epitopes were recognized by CD4+ T cells from HLA class IItransgenic strain. Overall, 17 out of the 18 encoded peptides were recognized. The induced T cell response had a polyfunctional type 1 cytokine profile, including IFN- , TNF- and IL-2. The vaccine also induced long-lived central memory CD4+ T cells, which might provide sustained help for CD8+ T cells. By virtue of inducing broad responses against conserved CD4+ T cell epitopes that can be recognized in the context of widely diverse, common HLA class II alleles, this vaccine concept may cope both with HIV genetic variability and increased population coverage. The vaccine may thus be usefull either as a standalone approach or as a source of cognate help for HIV-specific CD8+ T cells elicited by conventional immunogens, eliciting responses in a wide proportion of vaccinees
540

Transferência de anticorpos reativos com intiminas &#945;, &#946;, &#947; de Escherichia coli pela placenta e aleitamento materno: determinação quantitativa em soros de recém-nascidos e soros e colostros de suas mães / Transference of antibodies reactive with intimins &#945;, &#946; and &#947; of Escherichia coli by placenta and breastfeeding: quantitative determination in the sera of newborns and the colostrum and sera of their mothers

Silvia Patricia Nuñes Vaca 14 April 2010 (has links)
Intimina é uma adesina de natureza protéica das bactérias diarreiogênicas Escherichia coli enteropatogenica (EPEC) e enterohemorrágica (EHEC), capazes de induzir a lesão \'attaching e effacing\' em enterócitos. Os principais subtipos de intiminas de EPEC e EHEC prevalentes no Brasil são &#945;, &#946; e &#947;. Nosso objetivo foi investigar a transferência de anticorpos maternos anti-intiminas aos recém-nascidos de mães saudáveis de São Paulo, Brasil. Foram pesquisados anticorpos SIgA no colostro e IgG no soro de 50 mulheres saudáveis e no soro de cordão umbilical de seus recém-nascidos, por ELISA utilizando como antígeno proteínas recombinantes purificadas das regiões conservadas e variáveis de intiminas &#945;, &#946; e &#947;. As concentrações de anticorpos no colostro foram superiores quando comparadas com as concentrações do soro para todos os tipos de intiminas. Não se observaram diferenças estatísticas entre as concentrações de anticorpos reativos com as diferentes intiminas nas amostras de colostro. As concentrações de anticorpos reativos com a região conservada da intimina foram significativamente mais elevadas em comparação com as regiões variáveis no soro dos grupos de mães e de recém-nascidos. Houve alta correlação entre todos os anticorpos anti-intiminas nas amostras de colostro. Comparando-se as concentrações de anticorpos séricos, os coeficientes foram maiores entre anti-&#945; e anti-&#946; que entre os outros pares. Nossos resultados confirmam a transferência de anticorpos maternos para o recém-nascido pela placenta e pelo aleitamento materno e reforça o efeito protetor da amamentação contra infecção por EPEC. / Intimin is a proteic adhesin of enteropatogenic (EPEC) and enterohemorragic (EHEC) Escherichia coli, capable of inducing attachment and effacement lesion in enterocytes. The main subtypes of intimins of EPEC and EHEC prevalent in Brazil are &#945;, &#946; and &#947;. Our aim is to investigate the transference of maternal anti-intimin antibodies to the newborns of healthy mothers from Sao Paulo, Brazil. IgG and SIgA antibodies were determined in sera and colostrum from 50 healthy women and cord sera from their newborns, by ELISA using as antigens purified recombinant proteins, conserved and variable regions of &#945;, &#946; and &#947; intimins. The IgA antibody concentrations of colostrum are higher than IgG antibodies in serum for all intimins and there were no statistical differences between them in colostrum samples. The concentrations of antibodies reactive with the conserved region of intimin are significantly higher compared to the variable regions in the sera groups, mothers and newborns. There were high correlation coefficients between all the anti-intimins antibodies in colostrum samples. In the comparison of the seric antibody concentrations, the coefficients were higher between anti-&#945; and anti-&#946; than all the other pairs. Our results confirm the transference of maternal antibodies to the newborns by placenta and breastfeeding and reinforce the high protection effect of breastfeeding against EPEC infection.

Page generated in 0.0678 seconds